The Mild Behavioral Impairment Checklist for Parkinson's Disease: An Ancillary Instrument in Cognitive Assessment

Gabriel D Pinilla-Monsalve1,2, Yuan P Song1,3, Alexandru Hanganu1,3

  • 1Centre de recherche de l'Institut universitaire de gériatrie de Montréal, Montreal, Quebec, Canada.

Abstract

Insights

A revised Mild Behavioral Impairment Checklist (MBI-C) shows improved psychometric properties for identifying neuropsychiatric symptoms in Parkinson's disease (PD). This validated tool aids in detecting cognitive impairment risk in PD patients.

Area of Science:

  • Neuroscience
  • Clinical Psychology
  • Gerontology

Background:

  • Mild behavioral impairment (MBI) presents as neuropsychiatric symptoms (NPS) in later life, potentially indicating dementia.
  • In Parkinson's disease (PD), MBI correlates with cognitive decline, brain changes, and altered connectivity.
  • The MBI Checklist (MBI-C) assesses sustained behavioral changes for neurodegeneration risk, but requires validation in PD.

Purpose of the Study:

  • To validate the MBI-C's psychometric properties in a Canadian PD cohort.
  • To develop and propose a revised MBI-C optimized for PD assessment.
  • To evaluate the revised MBI-C's utility in identifying cognitive impairment in PD.

Main Methods:

  • The MBI-C was administered to 406 PD patients from the Canadian Open Parkinson Network.
  • Construct validity was assessed using exploratory factor analysis.
  • Concurrent and criterion validities were examined against MDS-UPDRS, NPI, and MoCA.

Main Results:

  • The original 34-item MBI-C had significant floor effects (24.9%).
  • A 24-item, 5-factor MBI-C demonstrated good internal consistency (Cronbach's α = 0.856).
  • The revised MBI-C showed moderate concurrent validity with the NPI (ICC = 0.633) and a cutoff score of 6|7 for cognitive impairment.

Conclusions:

  • The revised MBI-C offers improved psychometric performance for MBI assessment in PD.
  • The revised checklist demonstrates acceptable specificity for cognitive impairment.
  • Future research should explore subtle MBI manifestations, patient-caregiver agreement, and predictive validity for cognitive decline.